0001355250-12-000009.txt : 20120126 0001355250-12-000009.hdr.sgml : 20120126 20120125213028 ACCESSION NUMBER: 0001355250-12-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120103 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events FILED AS OF DATE: 20120126 DATE AS OF CHANGE: 20120125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellceutix CORP CENTRAL INDEX KEY: 0001355250 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134303398 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52321 FILM NUMBER: 12545919 BUSINESS ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 BUSINESS PHONE: (978)-633-3623 MAIL ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 FORMER COMPANY: FORMER CONFORMED NAME: EconoShare, Inc. DATE OF NAME CHANGE: 20060306 8-K 1 f8k302801.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report January 25, 2012

(Date of earliest event reported: January 3, 2012)

 

CELLCEUTIX CORPORATION

 

  

 

 

Nevada

 

30-0565645

 

 

 

(State or Other Jurisdiction of

 

(I.R.S. Employer

Incorporation or Organization)

 

Identification Number)

 

 

100 Cumming Center, Suite 151-B

Beverly, MA  01915

 

 

 

 (Address of principal executive offices and zip code)

 

(978)-633-3623

(Registrant's telephone number, including area code) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

o

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

o

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

o

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

 

 

 

 

Item 3.02 Unregistered Sales of Equity Securities

 

 

On January 11, 2012,  we issued 200,000  common shares of our company stock to a consultant for services rendered.  Shares were valued at $90,000 based on the closing bid price of $0.45 per share.   The shares were issued pursuant to the exemption from registration provided for under Rule 506 of Regulation D, promulgated under the United States Securities Act of 1933, as amended. 

 

Item 8.01 Other Events

 

 On January 3,  we made payment under the Convertible Note issued to Putnam Partners LLC dated as of January 1, 2011,   the principal amount of $166,942.21 and accrued interest  of  $14,983.64 for an aggregate of $181,925.85 upon presentment for payment.

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  January 25, 2012

 

 

 

 

 

 

CELLCEUTIX CORPORATION

 

 

 

 

 

 

 

 

By:  

/s/ Leo Ehrlich

 

 

 

Chief Executive Officer